[Malignant lymphoma NHL]

Area of Science:

• Oncology
• Hematology
• Clinical Medicine

Context:

• Evaluation of long-term survivors of malignant lymphoma treated since 1976.
• Analysis of treatment protocols including radiotherapy and anthracycline-based chemotherapy.
• Assessment of survival rates across different lymphoma stages and patient demographics.

Purpose:

• To assess the long-term efficacy and survival outcomes of various treatment modalities for malignant lymphoma.
• To identify factors influencing relapse-free and overall survival in lymphoma patients.
• To evaluate treatment effectiveness in specific patient subgroups, including the elderly and those with localized disease.

Summary:

• Radiotherapy for stage I lymphoma ( < 5 cm) yielded an 83% 5-year relapse-free survival.
• Adriamycin-based chemotherapy for nodal localized lymphoma resulted in a 41% 5-year survival rate.
• Stage II lymphoma involving Waldeyer's ring treated with chemotherapy showed a 92% complete response and 83% 5-year survival.
• Advanced stage lymphoma had a 36% 5-year survival, with 69% long-term survival in complete responders.
• Elderly patients (≥70 years) had a 31% 5-year survival, but localized lymphoma patients receiving chemotherapy had 77% survival.

Impact:

• Radiotherapy remains a viable option for early-stage malignant lymphoma.
• Anthracycline-based chemotherapy demonstrates significant survival benefits, particularly in localized disease and older adults.
• Chemotherapy is effective for advanced lymphoma, with complete response correlating with long-term survival.
• Treatment strategies can be optimized for elderly patients with localized lymphoma, improving outcomes.
• Findings inform treatment decisions and prognostication for diverse lymphoma patient populations.